R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 17/7/20

3 weeks ago By Josh Neil
  • Share on

  • Facebook
  • Linkedin
Proventa International Weekly News

In the news this week, despite significant alarms recently that GSK’s belantamab mafodotin could endanger patients’ eyes, the multiple myeloma drug has been approved by expert advisers. In other news, Novartis promises to make no profit from 15 of its COVID drugs sent to developing countries; and J&J is set to begin human testing of its own COVID-19 drug.

GSK’S MULTIPLE MYELOMA DRUG FDA-APPROVED DESPITE SAFETY FEARS – Despite FDA concerns around danger to patients’ eyes, GSK’s first-in-class multiple myeloma drug belantamab mafodotin has been backed by a panel of FDA expert advisers. The drug is expected to The regulatory is expected to come to a final decision in the next few weeks. 

ROCHE AND BLUEPRINT SIGN $1.7 BILLION DEAL ON CANCER DRUG – Roche and cancer drug company Blueprint have signed a deal worth up to $1.7 billion over pralsetinib, a drug targeting tumours with RET mutations. The two companies will equally market the drug and share profits and losses in the U.S. This deal will see Roche come into competition with Eli Lilly, whose RET inhibitor is already approved by the FDA. 

NOVARTIS PROMISES TO MAKE NO PROFIT FROM 15 COVID DRUGS IN POOR COUNTRIES – Novartis’s Sandoz unit has promised to offer 15 generic and over-the-counter medicines for no profit to developing countries while the COVID-19 pandemic continues. The range of drugs will cover cardiovascular and gastrointestinal diseases, and in particular dexamethasone, which has shown to cut death rates in severely ill coronavirus patients. 

In other news:

Clinical Trials
Bayer/Merck’s heart failure drug vericiguat receives FDA fast review
J&J to begin human testing of COVID-19 drug

Manufacturing
Moderna begins production of COVID vaccine for at-risk patients
FDA reveals plans for restarting domestic inspections

That’s all for now. See you next week!

Joshua Neil, Editor
Proventa International

To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.

More news

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

4 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 10/7/20

In the news this week, the Trump Administration has made another deal to acquire all initial doses of a potential COVID-19 drug, in this case Regeneron’s REGN-COV2. This follows their acquisition of the first batches of Gilead’s remdesivir last week....

4 weeks ago

Clinical Trial Continuity and the Impact of COVID-19

Here's a second chance to catch the fascinating keynote panel discussion with IQVIA, Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for a post-Covid world and ensure your clinical trials are more patient-centric than...

4 weeks ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Clinical Trial Continuity and the Impact of COVID-19

Here's a second chance to catch the fascinating keynote panel discussion with IQVIA, Eli Lilly and Co., EMD Serono/Merck KGaA and Janssen. See how you can prepare for a post-Covid world and ensure your clinical trials are more patient-centric than...

4 weeks ago

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

1 month ago
R&D,Bioprocess,Clinical Development,Weekly Roundups

Weekly News Round-up – 3/7/20

Big news this week, with the U.S. administration buying up remdesivir’s stock for the next three months, ensuring no other country will receive any. In other news, Pfizer and BioNTech’s own covid drug has shown promising results in early trials,...

1 month ago
Working With us

Interested?
Reserve your space